This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biodel Fails to Excite Investors With Me-Too Mealtime Insulin

BIOD Market Cap ChartBIOD Market Cap data by YCharts

DANBURY, Conn. (TheStreet) -- In our current effervescent biotech market, a press release from a company with a small market value announcing positive clinical trial results has been usually good for a hefty bump in stock price.

Biodel (BIOD) tried following the playbook Monday with a much-anticipated press release touting positive mid-stage results on its "ultra rapid-acting" mealtime insulin. The market didn't play along, however, sending Biodel shares down 17 percent to $4.17 at Monday's open.

Now, to be fair to Biodel, the stock had already doubled in value this year, with most of the gains coming this summer in anticipation of the BIOD-123 study results. Still, the lack of a follow through is a disappointment and likely reflects investor ambivalence about the ultimate commercial potential of BIOD-123.

There was a paucity of data announced Monday to differentiate Biodel's mealtime insulin from those already on the market, including Eli Lilly's (LLY) Humalog and Novo Nordisk's (NVO) Novolog. In the phase II study, BIOD-123 looks very much like Humalog from an efficacy standpoint, which isn't very exciting.

Biodel shares are also likely down Monday because, in the phase II study, 14 percent of diabetes patients found BIOD-123 injections to be painful compared to 1.5 percent of patients treated with Humalog. None of the injection site reactions were characterized as severe, nor did they force patients to discontinue the study.

That's a mild positive, but it's not exactly an encouraging sign for Biodel's future marketing purposes when "Ouch! That shot hurts!" is the most distinguishing characteristics of BIOD-123.

Biodel carried a market cap of about $100 million going into the release of BIOD-123 study results. Bulls argued that market value was unjustifiably low for a company with a product ready for phase III studies. It's not an bad argument to make, particularly with the way investors have generally over-reacted to "positive" data announcement this year.

But for whatever reason, Biodel isn't getting the benefit of the doubt Monday. Not yet, at least. We'll see if sell-side analysts can rally their clients to buy the stock later today.

One more note: If Biodel shares are too cheap, then MannKind (MNKD) , which is also developing a dodgy rapid-acting mealtime insulin (inhaled rather than injected) is still way too expensive. The valuation gap between the two companies should narrow but mainly by MannKind's stock price falling.

-- Reported by Adam Feuerstein in Boston.

Stock quotes in this article: BIOD, MNKD, LLY, NVO 
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs